• Sher Bahadar Khan
  • Hameed ullah
  • Lubna Noor
  • Muhammad Hafeezullah
  • Zahid Aslam Awan
  • Shahab ud Din


Background: Anticoagulant effect of clopidogrel is of utmost importance in coronary artery disease,especially in prevention of coronary stent thrombosis. Recently, many new local brands of clopidogrelhave been launched, with unknown efficacy. This study was conducted with the aim to compare twolocally prepared clopidogrel brands, in terms of the effect of a loading dose of 600 mg on inhibition ofplatelet aggregation in patients with coronary artery disease. Methods: This was a double blindrandomised study. Sample population consisting of 35 patients, were admitted at Lady ReadingHospital, Peshawar, for the management of coronary artery disease. Baseline platelet aggregation of allthese patients was measured. These patients were divided in two groups randomly. Group-A consistingof 18 patients was given brand ‘A’ clopidogrel 600 mg, while Group-B consisting of 17 patients wasgive brand ‘B’ of clopidogrel 600 mg. The platelet aggregation of both groups was then measured atbaseline, and at 2, 4, and 6 hours after taking the loading dose of 600 mg. Results: Platelet aggregationtime at baseline in Group-A was 2.61±2.28 sec. and in Group-B it was 2.24±1.52 sec. (p=0.57). After 2hours of clopidogrel administration in Group-A the platelet aggregation time was 1.44±1.58 sec. and inGroup-B it was 1.53±1.107 sec. (p=0.85). Platelet aggregation time after 4 hours in Group-A was0.28±0.57 sec. and in Group-B 1.06±1.03 sec. (p=0.009), and after 6 hours it was 0.00±0.00 sec. inGroup-A and in Group-B it was 0.59±0.71 sec. (p=0.001). Conclusion: The two brands of clopidogrelhad a significant difference in their effect on inhibition of platelet aggregation. Different brands ofclopidogrel may not be equally effective.Keywords: Platelet Aggregation, Clopidogrel, Coronary Artery Disease


Sabatine MS, McCabe CH, Cannon CP. Design and rationale

of clopidogrel as adjunctive reperfusion therapy

(CLARITY)- thrombosis in myocardial infarctio (TIMI) 28

trial. Am Heart J 2005;149:227–33.

Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel.

Circulation 1999;348:1329.

George CM, Kayser Sr, Adler DS. Thromboembolic disease

in; Herfindal ET, Hirshman, jl, Eds. Clinical pharmacy and

therapeutics. 6th edition. Baltimore MD: Williams and

Wilkins; 1996.p.959–72.

Diaz Linares M, Rodvold KA, Friedenberg WR. Coagulation

disorders. In; Dipiro jt, Talbert RT, Eds Pharmacotherapy, a

Pathophysiology Approach 4th ed. Stamford: Appletion and

Lange; 1999.p.1549–72.

Easton JD. Evidence with Antiplatelet Therapy and ADPreceptor Antagonist. Cerebrovasc Dis 2003;16(Suppl 1):20–

CAPRIE steering committee. A randomized, blinded, trial of

clopidogrel versus aspirin at risk of ischemic events

(CAPRIE). Lancet 1996;348:1329–39.

Antiplatelet Trialist Collaboration. Collaborative overview of

randomized trials of antiplatelet therapy, Prevention of death,

myocardial infarction and stroke by prolonged antiplatelet

therapy in various categories of patients. BMJ 1994;308:81–

The Clopidogrel in Unstable Angina to Prevent Recurrent

Events Trial Investigators. Effects of clopidogrel in addition

to aspirin in patients with Ischemic heart diseases without

ST-segment elevation. N Engl J Med 2001;345:494–502.

Born GVR. Quantitative investigations into the aggregation

of blood platelets. J. Physiol Lond 1962;162:67–8.

Clopidogrel product monograph, May 2003.

Iris M, Melchior S, Silja R. Effect of High Loading Dose of

Clopidogrel on Platelet Functions in Patients Undergoing

Coronary Stent Placement. Heart 2001;85:92–3.

Iris M, Felicitas B, Christian S. Prevalence of clopidogrel

non-responders among patients with stable angina pectoris

scheduled for elective coronary stent placement. Thromb

Haemost 2003;89:78–7.

Yan BP, Clark DJ, Ajani AE. Oral antiplatelet therapy and

percutaneous coronary intervention. Expert Opin

Pharmacother 2005;6:3–12.

Bertrand ME, Rupprecht H-J, Urban P. Double-blind study of

the safety of clopidogrel with and without a loading dose in

combination with aspirin compared with ticlopidine in

combination with aspirin after coronary stenting: the

clopidogrel aspirin stent international cooperative study

(CLASSICS). Circulation 2000;102:624–9.

Yusuf S, Zhao F, Mehta SR. For the Clopidogrel in Unstable

Angina to Prevent Recurrent Events Trial Investigators.

Effects of clopidogrel in addition to aspirin in patients with

acute coronary syndromes without ST-segment elevation. N

Engl J Med 2001;345:494–502.

Mehta SR, Yusuf S, Peters RJG. For the Clopidogrel in

Unstable angina to prevent Recurrent Events trial (CURE)

Investigators. Effects of pretreatment with clopidogrel and

aspirin followed by long-term therapy in patients undergoing

percutaneous coronary intervention: the PCI-CURE study.

Lancet 2001;358:527–33.

Steven R. Steinhubl, Peter B. For the CREDO Investigators

Early and Sustained Dual Oral Antiplatelet Therapy

Following Percutaneous Coronary Intervention: A

Randomized Controlled Trial. JAMA 2002;288:2411–20.

COMMIT/CCS-2 (Clopidogrel and Metoprolol in

Myocardial Infarction Trial), ACC's 54 Annual Scientific

Sessions in Orlando, Florida, 9 March 2005.

Marc SS, Christopher PC, Michael GC. CLARITY-TIMI 28

(Clopidogrel as adjunctive reperfusion therapy-thrombolysis

in myocardial infarction study 28). N Engl J Med




Most read articles by the same author(s)

1 2 3 > >>